


AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-52. (Cancelled)


53. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound

having a ~~general~~ formula (I)



in which

X represents a group of formula (II)



where Z is a $-(\text{CH}_2)_m$ group, with $m = 8$ to 21 ,

$n = 0$ or 1

and $\text{Y} = \text{R}_3$,

R₁ and R'₁, identical to or different from one another, being chosen from H, alkyl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, OSO₂-alkyl, OSO₂-aryl, OSO₂- heterocycle, O-CO-S-alkyl, O-CO-NH-alkyl, O-CO-O-alkyl, O-CO-O-aryl, O-CO- S-aryl, O-CO- NH-aryl, PO(O-alkyl)₂, PO(O-aryl)₂, CO-O-CH₂-aryl, or cycloalkyl,

R₂ and R'₂, identical to or different from one another, being chosen from H, alkyl, CO-O-CH₂-aryl, CO-O-alkyl, or cycloalkyl,

R₃ and R'₃, identical to or different from one another, representing H, alkyl, CO-O-aryl, COO-CH(R)-O-CO-alkyl, PO(O-alkyl)₂, PO(O-aryl)₂, PO(ONa)₂, or CO-O-CH(R)-aryl,

R being H or alkyl,

and

R₁ and R₂, and/or R'₁ and R'₂, or R₂ and R₃ and/or R'₂ and R'₃, or R₁, R₂ and R₃ and/or R'₁, R'₂ and R'₃, together form a nitrogenated mono heterocycle with the nitrogen atom or atoms to which they are respectively attached, or also,

R₂ and R₃ and/or R'₂ and R'₃ can be the same ~~substituent or different~~, [[or]] double-bonded to the nitrogen, [[or]] cyclized with, respectively, R₁ or R'₁ in order to form a heterocycle, if appropriate and ~~R₂, R₃, R'₂ and R'₃ may be independently~~ substituted by R_a, which is chosen from H, alkyl, alkyl substituted by 1, 2 or 3 halogen atoms, aryl, CO-O-alkyl, CO-O-aryl, -CO-OH, -CO-NH₂, -CN, -CO-NH-alkyl, -CO-NH-aryl, -CO-N-(alkyl)₂, CO-nitrogenated heterocycle, CO-oxygenated heterocycle, CO-

nitrogenated and oxygenated heterocycle, NH_2 , NH -alkyl, $\text{N}(\text{alkyl})_2$, nitrogenated heterocycle, oxygenated heterocycle, nitrogenated and oxygenated -heterocycle, -O-alkyl, -O-aryl, -O- CH_2 -aryl, CH_2NH_2 , CH_2NH -alkyl, CH_2N -dialkyl, CH_2NH -aryl, CH_2 -nitrogenated heterocycle, CH_2 -oxygenated heterocycle, CH_2 -nitrogenated and oxygenated heterocycle, CH_2 -CO-OH,

or a pharmacologically acceptable salt thereof,

in association with an inert pharmaceutical vehicle,

with the proviso that when R_1 and R_2 form a heterocycle, and R'_1 and R'_2 form the same heterocycle as is formed with R_1 and R_2 , and $n=0$, and R_3 is hydrogen or alkyl, and R'_3 is hydrogen or alkyl, or

when R_1 and R_3 form a heterocycle, and R'_1 and R'_3 form the same heterocycle as is formed with R_1 and R_3 , and $n=0$, and R_2 is hydrogen or alkyl, and R'_2 is hydrogen or alkyl,

then m is 12-21.


54. (Previously Presented) The pharmaceutical composition according to claim 53, in a form administrable by oral route, by injectable route, or by rectal route.

Claims 55-57. (Cancelled)

58. (Currently Amended) The pharmaceutical composition of claim ~~[[55]]53~~ for the treatment of ~~wherein said infectious disease is malaria.~~

59. (Previously Presented) A pharmaceutical composition according to claim 53 wherein the pharmaceutically effective amount is an amount effective to treat malaria.

60. (Currently Amended) A pharmaceutical composition according to claim 53 wherein said at least one compound has the ~~general~~ formula (V)



or a pharmacologically acceptable salt thereof.

61. (Previously Presented) A pharmaceutical composition according to claim 60 wherein in said compound or pharmacologically acceptable salt thereof R₁, R'₁, R₂, R'₂, R₃ and R'₃ are independent of one another.

62. (Previously Presented) A pharmaceutical composition according to claim 61, wherein in said compound or pharmacologically acceptable salt thereof R₁ and/or R'₁ do not represent a hydrogen atom, whilst R₃ and/or R'₃, R₂ and/or R'₂, represent a hydrogen atom.

63. (Previously Presented) A pharmaceutical composition according to claim 62, wherein in said compound or pharmacologically acceptable salt thereof R₁ and/or R'₁, and R₂ and/or R'₂ represent a hydrogen atom, whilst R₃ and/or R'₃ are different from a hydrogen atom.

64. (Previously Presented) A pharmaceutical composition according to claim 60, wherein in said compound or pharmacologically acceptable salt thereof


R_1 and R_2 , and/or R'_1 and R'_2 , or

R_2 and R_3 , and/or R'_2 and R'_3 , or

R_1 , R_2 and R_3 and/or R'_1 , R'_2 and R'_3 together form a heterocycle.


65. (Previously Presented) A pharmaceutical composition according to claim 64, wherein in said compound or pharmacologically acceptable salt thereof

R_1 and R_2 as well as R'_1 and R'_2 form a heterocycle, having the general formula (VI)



66. (Previously Presented) A pharmaceutical composition according to claim 65, wherein in said compound or pharmacologically acceptable salt thereof R_1 and/or R'_1 represent a hydrogen atom, and R_2 and R_3 , and/or R'_2 and/or R'_3 represent a $-(CH_2)_p-$ group, wherein p is an integer from 1 to 5.

67. (Previously Presented) A pharmaceutical composition according to claim 53, wherein in said compound or pharmacologically acceptable salt thereof R_2 and R_3 and/or R'_2 and R'_3 form a same substituent and form together with R_1 or respectively R'_1 a bis-oxadiazole of formula (VIII.)



68. (Previously Presented) A pharmaceutical composition according to any one of claims 60-67, in a form administrable by oral route, by injectable route, or by rectal route.

69. (Previously Presented) A pharmaceutical composition of any one of claims 53, 54 or 60-67, wherein the pharmaceutically effective amount is an amount effective to treat malaria.